Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKF-INS Glargine
- Development stage
- Unknown
- Lead developer
- Nanjing King Friend Biochemical Pharmaceutical
- Modality
- Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
NKF-INS Glargine is a long-acting insulin analog biosimilar being developed by Xentria in partnership with Meitheal. It is designed as a biosimilar to Sanofi's Lantus (insulin glargine). The drug acts as an agonist of the insulin receptor, mimicking the action of endogenous insulin to regulate glucose metabolism and maintain glycemic control. It is currently in Phase 1/2 clinical development, with studies utilizing the euglycemic clamp technique to demonstrate pharmacokinetic and pharmacodynamic similarity to both US-licensed and EU-approved versions of the reference product. The drug is intended for the treatment of diabetes mellitus within the endocrinology therapeutic area.
- Other names
- insulin glargine biosimilarXentria insulin glargine
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)INSR (Insulin receptor)
Beyond the preview
Go deeper on NKF-INS Glargine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKF-INS Glargine.